Breaking News Instant updates and real-time market news.

VOXX

VOXX

, CUDA

Barracuda

$23.33

-0.71 (-2.95%)

17:59
10/11/16
10/11
17:59
10/11/16
17:59

On The Fly: After Hours Movers

UP AFTER EARNINGS: VOXX (VOXX), up 13.9%... Barracuda (CUDA), up 7.2%... Blackhawk (HAWK), up 3%. ALSO HIGHER: Intellipharmaceutics (IPCI), up 14.5% after it signed a license and commercial supply pact with Mallinckrodt (MNK)... Idera Pharmaceuticals (IDRA), up 6.1% after Baker Bros. Advisors reported a 7.2% stake in the company. LOWER: Fortinet (FTNT), down 13.9% after it reported lower than expected preliminary third quarter results and increased its share repurchase program... Cybersecurity firms Palo Alto Networks (PANW), Proofpoint (PFPT), and FireEye (FEYE), down a respective 4.45%, 4.25%, and 2.3% after Fortinet said that its preliminary Q3 results were primarily impacted by the lengthening of deal cycles as enterprises become more strategic with their purchasing decisions and buying with less urgency than last year.

VOXX

VOXX

CUDA

Barracuda

$23.33

-0.71 (-2.95%)

HAWK

Blackhawk

$31.93

-0.27 (-0.84%)

IPCI

Intellipharmaceutics

$2.83

-0.01 (-0.35%)

MNK

Mallinckrodt

$68.16

-2.62 (-3.70%)

IDRA

Idera Pharmaceuticals

$1.81

-0.14 (-7.18%)

FTNT

Fortinet

$34.09

-0.9 (-2.57%)

PANW

Palo Alto Networks

$155.48

-4.26 (-2.67%)

PFPT

Proofpoint

$71.02

-2.4 (-3.27%)

FEYE

FireEye

$13.30

-0.46 (-3.34%)

  • 11

    Oct

  • 12

    Oct

  • 13

    Oct

  • 13

    Oct

  • 20

    Oct

  • 20

    Oct

  • 23

    Oct

  • 03

    Nov

  • 14

    Nov

  • 08

    Dec

  • 12

    Dec

  • 14

    Dec

VOXX VOXX

11/11/15
OPCO
11/11/15
INITIATION
Target $9
OPCO
Outperform
VOXX initiated with an Outperform at Oppenheimer
Target $9.
11/12/15
11/12/15
INITIATION

On The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: Accuray (ARAY) initiated with a Sell at Citi... Becton Dickinson (BDX) initiated with a Neutral at Citi... Boston Scientific (BSX) initiated with a Buy at Citi... Bruker (BRKR) initiated with a Buy at Stifel... C.R. Bard (BCR) initiated with a Buy at Citi... Cepheid (CPHD) initiated with a Buy at Stifel... CorMedix (CRMD) initiated with a Buy at Rodman & Renshaw... CoreSite Realty (COR) initiated with a Buy at BB&T... Digital Realty (DLR) initiated with a Buy at BB&T... DuPont Fabros (DFT) initiated with a Hold at BB&T... Duke Realty (DRE) initiated with a Hold at BB&T... Edwards Lifesciences (EW) initiated with a Sell at Citi... Electronic Arts (EA) initiated with an Outperform at Oppenheimer... EyeGate (EYEG) initiated with a Buy at Maxim... Glu Mobile (GLUU) initiated with a Perform at Oppenheimer... Integra LifeSciences (IART) initiated with a Buy at Citi... Intuitive Surgical (ISRG) initiated with a Buy at Citi... Mast Therapeutics (MSTX) initiated with a Buy at Maxim... Medgenics (MDGN) initiated with a Buy at Needham... Novocure (NVCR) initiated with a Buy at Evercore ISI... Prologis (PLD) initiated with a Hold at BB&T... QIAGEN (QGEN) initiated with a Hold at Stifel... Rocket Fuel (FUEL) initiated with a Neutral at Boenning & Scattergood... STAG Industrial (STAG) initiated with an Underweight at BB&T... Stryker (SYK) initiated with a Sell at Citi... Tremor Video (TRMR) initiated with an Outperform at Boenning & Scattergood... VOXX (VOXX) initiated with an Outperform at Oppenheimer... Varian Medical (VAR) initiated with a Neutral at Citi... Yahoo (YHOO) initiated with an Outperform at Boenning & Scattergood... YuMe (YUME) initiated with a Neutral at Boenning & Scattergood... Zimmer Biomet (ZBH) initiated with a Sell at Citi.
CUDA Barracuda
$23.33

-0.71 (-2.95%)

10/04/16
IMPC
10/04/16
DOWNGRADE
Target $20
IMPC
Underperform
Barracuda downgraded to Underperform from In-Line at Imperial Capital
Imperial Capital analyst Michael Kim downgraded Barracuda Networks to Underperform from In-Line citing valuation, but raised his price target on the stock to $20 from $17.
08/30/16
PACS
08/30/16
UPGRADE
Target $30
PACS
Overweight
Barracuda upgraded to Overweight from Sector Weight at Pacific Crest
Pacific Crest analyst Rob Owens upgraded Barracuda Networks to Overweight saying he's seeing improved trends due to the company's renewed product alignment and cloud-centric channel marketing campaign. The analyst has a $30 price target for the shares.
08/30/16
PACS
08/30/16
DOWNGRADE
PACS
Sector Weight
Imperva downgraded to Sector Weight from Overweight at Pacific Crest
Pacific Crest analyst Rob Owens downgraded Imperva (IMPV) to Sector Weight saying the company's fundamentals continue to be challenged. Iimproved performance will take longer than the Street appreciates, Owens tells investors in a research note. The analyst sees a "limited number" of strategic suitors for Imperva and thinks the current share price could prevent "meaningful upside" should a buyer step in. Owens coupled the downgrade with upgrades this morning of Barracuda (CUDA) and Fortinet (FTNT) to Overweight.
08/30/16
08/30/16
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. McDonald's (MCD) upgraded to Outperform from Neutral at Baird by analyst David Tarantino, who believes the stock's risk/reward has become more favorable following the year-to-date underperformance. The analyst admits that slower U.S. industry demand trends and challenging upcoming comparisons pose a "short-term headwind," but thinks the company's "attractive" dividend yield can help to limit further downside risk in the shares. 2. United Continental (UAL) upgraded to Outperform from Market Perform at Raymond James, with analyst Savanthi Syth applauding the selection of Scott Kirby as President and Andrew Levy as CFO. Syth said both have strong industry experience and has increased conviction United will reduce its margin gap relative to its peers over the next 12-18 months. 3. VMware (VMW) upgraded to Buy from Neutral by SunTrust analyst John Rizzuto, who says that the company has effectively diversified beyond its server virtualization roots. The analyst, who expects the company's revenue to bottom this year and accelerate through the end of the decade, raised his price target on the stock to $92 from $64. 4. Barracuda (CUDA) upgraded to Overweight from Sector Weight at Pacific Crest, as analyst Rob Owens said he's seeing improved trends due to the company's renewed product alignment and cloud-centric channel marketing campaign. 5. Fortinet (FTNT) upgraded to Overweight from Sector Weight at Pacific Crest by Rob Owens, who believes management's focus on enhanced profitability should drive share outperformance. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
HAWK Blackhawk
$31.93

-0.27 (-0.84%)

10/07/16
BOFA
10/07/16
DOWNGRADE
Target $34
BOFA
Neutral
Blackhawk downgraded to Neutral from Buy at BofA/Merrill
BofA Merrill Lynch analyst David Chu downgraded Blackhawk to Neutral from Buy, stating that the firm's channel checks indicate that conversions to EMV, the new standard for chip-based debit/credit card transactions, are taking longer than expected, which he believes could impact Blackhawk's 2016 guidance and expectations for 2017. Chu cut his price target on Blackhawk shares to $34 from $41.
10/07/16
10/07/16
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Tyson Foods (TSN) downgraded to Sell from Hold at Pivotal Research with analyst Timothy Ramey citing the broiler price-fixing alleged in the class action complaint filed on September 2. 2. SolarEdge (SEDG) was downgraded to Sell from Neutral at Goldman while the firm also downgraded First Solar (FSLR) to Neutral from Buy. 3. CIT Group (CIT) downgraded to Hold from Buy at Stifel with analyst Christopher Brendler saying investors should sell into the rally that will result from the "impressive" price that the company received for its aircraft business and the approval of its capital plan by the Fed. 4. Fifth Third (FITB) downgraded to Hold from Buy at Jefferies with analyst Ken Usdin saying the shares are reasonably valued following the recent rally. 5. Blackhawk (HAWK) downgraded to Neutral from Buy at BofA/Merrill with analyst David Chu saying the firm's channel checks indicate that conversions to EMV, the new standard for chip-based debit/credit card transactions, are taking longer than expected, which he believes could impact Blackhawk's 2016 guidance and expectations for 2017. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/21/16
09/21/16
UPGRADE

Outperform
Blackhawk upgraded to Outperform on valuation at CLSA
As previously reported, CLSA upgraded Blackhawk to Outperform from Market Perform and raised its price target to $36 from $34. Analyst Tom McCrohan said the recent pullback in shares provides a buying opportunity and said his overall thesis of operating leverage, EMV and earnings quality remains unchanged.
10/10/16
JEFF
10/10/16
NO CHANGE
Target $43
JEFF
Buy
Blackhawk recent selloff a buying opportunity, says Jefferies
Jefferies analyst Ramsey El-Assal recommends using the recent pullback in shares of Blackhawk Network as a buying opportunity. Revenue lost to chip cards should flow back into 2017, El-Assal tells investors in a research note. The analyst sees upside to the company's 2017 estimates and keeps a Buy rating on the shares with a $43 price target.
IPCI Intellipharmaceutics
$2.83

-0.01 (-0.35%)

10/04/16
BMUR
10/04/16
INITIATION
Target $8
BMUR
Buy
Intellipharmaceutics assumed with a Buy at Brean Capital
Brean Capital analyst Difei Yang assumed coverage of Intellipharmaceutics with a Buy rating and $8 price target.
MNK Mallinckrodt
$68.16

-2.62 (-3.70%)

09/21/16
MSCO
09/21/16
NO CHANGE
MSCO
Mallinckrodt's Ikaria acquisition underappreciated, says Morgan Stanley
Morgan Stanley analyst David Risinger said since the closing of the Ikaria acquisition, Mallinckrodt has quietly grown to be approximately 15% of 2017 estimates revenues and approximately 25% of 2017 estimated operating income. Given Ikaria's strong growth trends, Risinger estimates its valuation to be in the range of $3.9B-$4.3B, excluding Terlipressin pipeline asset, 78% more at the midpoint than Mallinckrodt's $2.3B purchase price.
08/26/16
UBSW
08/26/16
NO CHANGE
Target $92
UBSW
Buy
Skepticism on Acthar growth already priced into Mallinckrodt shares, says UBS
UBS analyst Marc Goodman said his investment thesis on Mallinckrodt remains unchanged, as he still sees an attractive valuation, has expectations its generics business will stabilize and believes that skepticism surrounding Acthar's growth is already priced into the stock. Goodman reiterated his Buy rating and $92 price target on Mallinckrodt shares.
08/24/16
PIPR
08/24/16
NO CHANGE
Target $112
PIPR
Overweight
Mallinckrodt price target raised to $112 from $103 at Piper Jaffray
Piper Jaffray analyst David Amsellem said his talks with Mallinckrodt management indicate that the company's contracting activity is providing greater standardization of Acthar coverage and generally making the process of getting an Acthar prescription filled more predictable. In turn, this should make it more likely that physicians and practices will more consistently prescribe the drug, Amsellem tells investors. Paired with additional clinical outcomes data, Amsellem sees high visibility for relatively strong volume growth over the long-term and raised his price target on Mallinckrodt shares to $112 from $103 while keeping an Overweight rating on the stock.
08/18/16
08/18/16
NO CHANGE

Mallinckrodt building new campus for Specialty Brands business in New Jersey
Mallinckrodt will build out a new campus for its Specialty Brands organizations in the Somerset Financial Center in Bedminster. Mallinckrodt will invest greater than $80M in New Jersey, and anticipates approximately 400 employees will occupy the new space in 1Q17. The company is also continuing its investment in St. Louis, Mo., having recently begun the next phase of construction at its downtown St. Louis manufacturing facility.
IDRA Idera Pharmaceuticals
$1.81

-0.14 (-7.18%)

12/07/15
PIPR
12/07/15
NO CHANGE
Target $7
PIPR
Overweight
Idera Pharmaceuticals data show 'impressive activity,' says Piper Jaffray
Piper Jaffray analyst Edward Tenthoff says the IMO-8400 data in Waldenstrom's Lymphoma that Idera Pharmaceuticals presented Saturday at the American Society for Hematology showed "impressive activity." This data is a clear signal of activity and validates toll-like receptor as a target, Tenthoff tells investors in a research note. He reiterates an Overweight rating on Idera with a $7 price target.
01/05/16
WEDB
01/05/16
INITIATION
Target $6
WEDB
Outperform
Idera Pharmaceuticals initiated with an Outperform at Wedbush
Target $6.
01/06/16
01/06/16
INITIATION

On The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: Arista Networks (ANET) initiated with a Neutral at UBS... Cerulean (CERU) initiated with a Buy at Janney Capital... Codexis (CDXS) initiated with a Buy at H.C. Wainwright... Colgate-Palmolive (CL) initiated with an Overweight at Atlantic Equities... Danone (DANOY) initiated with a Buy at HSBC... Demandware (DWRE) initiated with a Buy at BofA/Merrill... Diplomat Pharmacy (DPLO) initiated with an Overweight at Barclays... Edwards Lifesciences (EW) initiated with an Outperform at JMP Securities... Enterprise Products (EPD) initiated with an Outperform at Scotia Howard Weil... Green Brick (GRBK) initiated with a Market Perform at JMP Securities... Hoegh LNG (HMLP) initiated with an Accumulate at Seaport Global... Idera Pharmaceuticals (IDRA) initiated with an Outperform at Wedbush... Jack in the Box (JACK) initiated with a Neutral at SunTrust... New Jersey Resources (NJR) initiated with a Market Perform at Wells Fargo... Novadaq (NVDQ) initiated with an Outperform at JMP Securities... Ollie's Bargain Outlet (OLLI) initiated with a Buy at Johnson Rice... Procter & Gamble (PG) initiated with a Neutral at Atlantic Equities... Shake Shack (SHAK) initiated with a Neutral at SunTrust... Steel Dynamics (STLD) initiated with a Buy at Rosenblatt... Teladoc (TDOC) initiated with a Hold at Stifel... TripAdvisor (TRIP) initiated with a Neutral at Hilliard Lyons... Tyco (TYC) initiated with a Neutral at Buckingham... WGL Holdings (WGL) initiated with a Market Perform at Wells Fargo... Willis Towers Watson (WLTW) initiated with an Outperform at William Blair... bluebird bio (BLUE) initiated with a Buy at Janney Capital.
03/10/16
PIPR
03/10/16
NO CHANGE
Target $4
PIPR
Overweight
Idera Pharmaceuticals price target lowered to $4 from $7 at Piper Jaffray
Piper Jaffray analyst Edward Tenthoff lowered his price target for Idera Pharmaceuticals to $4 citing the removal of IMO-9200 from his model since the company is no longer developing the drug. The analyst keeps an Overweight rating on Idera following the company's Q4 results.
FTNT Fortinet
$34.09

-0.9 (-2.57%)

08/30/16
PACS
08/30/16
UPGRADE
Target $47
PACS
Overweight
Fortinet upgraded to Overweight from Sector Weight at Pacific Crest
Pacific Crest analyst Rob Owens upgraded Fortinet to Overweight saying management's focus on enhanced profitability should drive share outperformance. The analyst believes the company's "breadth of platform continues to resonate well with customers" and he has a $47 price target for the shares.
09/23/16
OPCO
09/23/16
NO CHANGE
OPCO
Outperform
Speculation suggests Imperva takeover in 'near sight,' says Oppenheimer
Oppenheimer analyst Shaul Eyal is not surprised to see the list of potential Imperva (IMPV) buyer candidates mentioned in an article from Bloomberg, which includes Cisco (CSCO), IBM (IBM), Fortinet (FTNT), Akamai (AKAM), and privately held Forcepoint. The analyst envisions Imperva's product line aligning particularly well with Cisco's and IBM's given the recent drive by both to expand their security offerings. Eyal sees a potential price target ranging between $55-$60 if the speculation has any merit and sufficient interest from multiple bidders. Oppenheimer has an Outperform rating on Imperva's shares.
PANW Palo Alto Networks
$155.48

-4.26 (-2.67%)

09/15/16
JMPS
09/15/16
NO CHANGE
JMPS
Palo Alto Networks outlook has improved, says JMP Securities
After meeting with Palo Alto's CFO, JMP SDecurities analyst Erik Suppiger says that the company's customers are keeping their hardware products longer but spending more on support and subscription services. The analyst thinks that the latter trend will "help offset" the deceleration in product revenue expected to occur in fiscal 2017. He raised his price target on the stock to $180 from $165 and keeps an Outperform rating on the shares.
09/12/16
RSBL
09/12/16
INITIATION
Target $175
RSBL
Buy
Palo Alto Networks initiated with a Buy at Rosenblatt
Rosenblatt initiated Palo Alto Networks with a Buy and $175 price target. The analyst has confidence in management's ability to execute given the company's end-to-end security platform coupled with the strong adoption of the company's SaaS offerings.
09/19/16
IMPC
09/19/16
NO CHANGE
Target $190
IMPC
Outperform
Palo Alto win rates strong, can keep gaining share, says Imperial Capital
After meeting with Palo Alto Networks (PANW) management, Imperial Capital analyst Michael Kim noted that they highlighted their strong win rates when customers conduct head-to-head evaluations. Kim, who believes the company is gaining share in the network security market at the cost of Cisco (CSCO) and Check Point (CHKP), keeps an Outperform rating and $190 price target on Palo Alto shares.
09/22/16
FANA
09/22/16
NO CHANGE
Target $175
FANA
Overweight
Palo Alto Networks price target raised to $175 from $160 at First Analysis
First Analysis analyst Howard Smith said that after speaking with Palo Alto Networks CFO and CTO that he is more encouraged about the company's product pipeline strength and focused product approach. Smith, who expects the company's shift toward a greater proportion of subscription business to result in fast growth and improved free cash flow, raised his price target on Palo Alto shares to $175 from $160 and keeps an Overweight rating on the stock.
PFPT Proofpoint
$71.02

-2.4 (-3.27%)

10/04/16
DADA
10/04/16
INITIATION
Target $80
DADA
Neutral
Proofpoint initiated with a Neutral at DA Davidson
DA Davidson analyst Kevin Reevey initiated Proofpoint with a Neutral and an $80 price target due to premium valuation.
08/01/16
NEED
08/01/16
INITIATION
Target $88
NEED
Buy
Proofpoint initiated with a Buy at Needham
Target $88.
07/26/16
IMPC
07/26/16
NO CHANGE
Target $83
IMPC
Outperform
Proofpoint price target raised to $83 from $69 at Imperial Capital
Imperial Capital analyst Michael Kim raised his price target for Proofpoint to $83 citing a higher outlook following the company's Q2 results. The analyst thinks management's initial FY17 revenue guidance appears relatively conservative and he keeps an Outperform rating on the name.
07/25/16
IMPC
07/25/16
NO CHANGE
Target $69
IMPC
Outperform
Proofpoint guidance looks conservative, says Imperial Capital
Imperial Capital analyst Michael Kim thinks Proofpoint's initial FY17 revenue guidance appears conservative given the company's multiple growth drivers and his expectations for larger archiving transactions. The firm keeps an Outperform rating and $69 price target on Proofpoint shares.
FEYE FireEye
$13.30

-0.46 (-3.34%)

08/05/16
08/05/16
DOWNGRADE

Hold
Follow-up: FireEye downgraded to Hold at Wunderlich
As previously reported, Wunderlich downgraded FireEye to Hold and lowered its price target to $15 from $21. Analyst Ryan MacDonald said FireEye revenues and billings for Q2 came below expectations, resulting in another guidance down by management. The analyst said FireEye is clearly experiencing issues as a result of shifting dynamics in the security marketplace, combined with internal sales execution issues, creating too much uncertainty.
08/09/16
IMPC
08/09/16
DOWNGRADE
Target $15
IMPC
In-Line
FireEye downgraded to In-Line from Outperform at Imperial Capital
Imperial Capital analyst Michael Kim downgraded FireEye to In-Line citing a weaker billings outlook following the company's Q2 results. The analyst cut his price target for the shares to $15 from $25.
08/09/16
08/09/16
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Apache (APA) downgraded to Neutral from Buy at Citi with analyst Robert Morris citing limited upside to his slightly reduced price target of $53. 2. FireEye (FEYE) downgraded to In-Line from Outperform at Imperial Capital with analyst Michael Kim citing a weaker billings outlook following the company's second quarter results. 3. Infosys (INFY) downgraded to Hold from Buy at HSBC. 4. Waste Management (WM) downgraded to Equal Weight from Overweight at Barclays. 5. Patterson-UTI (PTEN) downgraded to Underperform from Neutral at Macquarie with analyst Walt Chancellor citing concerns about significant excess capacity persisting across the land drilling space. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
08/18/16
JMPS
08/18/16
NO CHANGE
JMPS
Few IT security names have negative read through from Cisco, say JMP Securities
JMP Securities analyst Erik Suppger noted that Cisco's (CSCO) advanced threat security solution grew 80% year-over-year. The analyst thinks that the system is taking share, and he believes that this bodes badly for FireEye (FEYE) and, to a more limited extent, vendors such as Palo Alto Networks (PANW) Check Point Software (CHKP), and Fortinet (FTNT). The analyst keeps an Outperform rating on Palo Alto and Fortinet and Market Perform ratings on Check Point and FireEye.

TODAY'S FREE FLY STORIES

SGMO

Sangamo

19:39
12/05/16
12/05
19:39
12/05/16
19:39
Hot Stocks
Sangamo reports preclinical, manufacturing data on SB-525, says IND on track »

Sangamo BioSciences…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

SGEN

Seattle Genetics

$66.26

-0.44 (-0.66%)

, BMY

Bristol-Myers

$55.55

-0.41 (-0.73%)

19:38
12/05/16
12/05
19:38
12/05/16
19:38
Hot Stocks
Seattle Genetics, Bristol-Myers: Data supports ADCETRIS, Opdivo combo »

Seattle Genetics (SGEN)…

SGEN

Seattle Genetics

$66.26

-0.44 (-0.66%)

BMY

Bristol-Myers

$55.55

-0.41 (-0.73%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

  • 07

    Dec

LGIH

LGI Homes

$32.34

0.45 (1.41%)

19:36
12/05/16
12/05
19:36
12/05/16
19:36
Hot Stocks
LGI Homes reports November home closings up 28.9% y/y »

LGI Homes announced 321…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CELG

Celgene

$116.56

-1.07 (-0.91%)

19:36
12/05/16
12/05
19:36
12/05/16
19:36
Hot Stocks
Celgene reports analysis of three CC-486 studies »

Celgene announced results…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

BLUE

bluebird bio

$72.15

2.4 (3.44%)

19:35
12/05/16
12/05
19:35
12/05/16
19:35
Hot Stocks
bluebird bio provides updates on HSC gene therapy programs »

bluebird bio provided…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AGIO

Agios Pharmaceuticals

$49.88

-7.09 (-12.45%)

19:33
12/05/16
12/05
19:33
12/05/16
19:33
Hot Stocks
Agios 'encouraged' by durable clinical activity of AG-120 »

Agios Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MRK

Merck

$60.25

-0.88 (-1.44%)

19:31
12/05/16
12/05
19:31
12/05/16
19:31
Hot Stocks
Merck: KEYNOTE-087 trial data shows oORR of 69%, CRR of 22.4% »

Merck announced updated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

  • 08

    Mar

TWX

Time Warner

$93.34

-0.46 (-0.49%)

, T

AT&T

$38.63

0.02 (0.05%)

19:29
12/05/16
12/05
19:29
12/05/16
19:29
Periodicals
Time Warner 'struggling to expand' HBO Now, NY Post says »

Time Warner (TWX) is…

TWX

Time Warner

$93.34

-0.46 (-0.49%)

T

AT&T

$38.63

0.02 (0.05%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

  • 07

    Dec

  • 07

    Dec

BP

BP

, REPYY

Repsol

$13.88

0.25 (1.83%)

19:18
12/05/16
12/05
19:18
12/05/16
19:18
Periodicals
BP acquires Repsol stake in Indonesia LNG plant, Reuters says »

BP (BP) has purchased…

BP

BP

REPYY

Repsol

$13.88

0.25 (1.83%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FOSUF

Fosun

19:12
12/05/16
12/05
19:12
12/05/16
19:12
Hot Stocks
Liberty Mutual to acquire Fosun subsidiary Ironshore for roughly $3B »

Liberty Mutual Insurance…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VZ

Verizon

$49.75

-0.06 (-0.12%)

, YHOO

Yahoo

$40.20

0.13 (0.32%)

18:54
12/05/16
12/05
18:54
12/05/16
18:54
Periodicals
AOL CEO 'cautiously optimistic' Verizon-Yahoo deal will go through, WSJ says »

AOL CEO Tim Armstrong…

VZ

Verizon

$49.75

-0.06 (-0.12%)

YHOO

Yahoo

$40.20

0.13 (0.32%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

  • 24

    Jan

TUWOY

Tullow Oil

$2.06

0.109 (5.58%)

18:46
12/05/16
12/05
18:46
12/05/16
18:46
Downgrade
Tullow Oil rating change  »

Tullow Oil downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GBNK

Guaranty Bancorp

$22.15

0.75 (3.50%)

18:43
12/05/16
12/05
18:43
12/05/16
18:43
Hot Stocks
Breaking Hot Stocks news story on Guaranty Bancorp »

Castle Creek raises stake…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ATKR

Atkore

$20.48

-0.18 (-0.87%)

18:41
12/05/16
12/05
18:41
12/05/16
18:41
Syndicate
Atkore files to sell 8M shares of common stock for holders »

The offering is being…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UTX

United Technologies

$107.42

-0.8 (-0.74%)

18:38
12/05/16
12/05
18:38
12/05/16
18:38
Hot Stocks
United Technologies CEO: No quid pro quo on taxes in Carrier deal with Trump »

Says Carrier agreement…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IPDN

Professional Diversity Network

$9.75

-0.01 (-0.10%)

18:37
12/05/16
12/05
18:37
12/05/16
18:37
Hot Stocks
Breaking Hot Stocks news story on Professional Diversity Network »

North Star cuts passive…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DHXM

DHX Media

$5.05

-0.36 (-6.65%)

18:33
12/05/16
12/05
18:33
12/05/16
18:33
Hot Stocks
Breaking Hot Stocks news story on DHX Media »

Luxor Capital cuts…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TPHS

Trinity Place

$10.02

0.08 (0.80%)

18:24
12/05/16
12/05
18:24
12/05/16
18:24
Hot Stocks
Trinity Place Holdings, Pacolet Milliken acquire Brooklyn building for $68.8M »

Trinity Place Holdings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SU

Suncor

$32.46

0.23 (0.71%)

18:07
12/05/16
12/05
18:07
12/05/16
18:07
Hot Stocks
Suncor Energy resolves C$1.3B tax dispute with Canada Revenue Agency »

Suncor Energy reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLRN

Acceleron

$34.90

-1.39 (-3.83%)

, CELG

Celgene

$116.56

-1.07 (-0.91%)

18:07
12/05/16
12/05
18:07
12/05/16
18:07
Hot Stocks
Acceleron, Celgene report Phase 2 data on luspatercept in beta-thalassemia »

Acceleron Pharma (XLRN)…

XLRN

Acceleron

$34.90

-1.39 (-3.83%)

CELG

Celgene

$116.56

-1.07 (-0.91%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

  • 06

    Dec

SNSS

Sunesis

$4.02

0.12 (3.08%)

17:54
12/05/16
12/05
17:54
12/05/16
17:54
Hot Stocks
Sunesis says new VALOR trial data show 'compelling durable survival outcomes' »

Sunesis Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

COUP

Coupa Software

$26.02

-0.27 (-1.03%)

, BOBE

Bob Evans

$46.77

1.05 (2.30%)

17:52
12/05/16
12/05
17:52
12/05/16
17:52
Hot Stocks
On The Fly: After Hours Movers »

UP AFTER EARNINGS: Coupa…

COUP

Coupa Software

$26.02

-0.27 (-1.03%)

BOBE

Bob Evans

$46.77

1.05 (2.30%)

TXMD

TherapeuticsMD

$6.17

0.04 (0.65%)

KMI

Kinder Morgan

$21.46

0.1 (0.47%)

SB

Safe Bulkers

LXRX

Lexicon

$15.64

0.66 (4.41%)

FET

Forum Energy

$23.20

1.15 (5.22%)

RCII

Rent-A-Center

$11.91

0.38 (3.30%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

  • 05

    Dec

  • 05

    Dec

  • 06

    Dec

  • 06

    Dec

  • 06

    Dec

  • 09

    Jan

  • 28

    Feb

  • 06

    Dec

KPTI

Karyopharm

$8.87

-0.41 (-4.42%)

17:47
12/05/16
12/05
17:47
12/05/16
17:47
Hot Stocks
Karyopharm presents updated Phase 1b STOMP data at ASH »

Karyopharm Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

BOBE

Bob Evans

$46.77

1.05 (2.30%)

17:47
12/05/16
12/05
17:47
12/05/16
17:47
Hot Stocks
Bob Evans says evaluating potential opportunities for value creation »

President and Chief…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

  • 06

    Dec

  • 09

    Jan

GOOG

Alphabet

$762.52

12.02 (1.60%)

, GOOGL

Alphabet Class A

$778.22

13.76 (1.80%)

17:46
12/05/16
12/05
17:46
12/05/16
17:46
Hot Stocks
Google posts job listing for 'conservative outreach' manager »

Google has posted a job…

GOOG

Alphabet

$762.52

12.02 (1.60%)

GOOGL

Alphabet Class A

$778.22

13.76 (1.80%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Jan

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.